Quantcast

PLEXERA® LLC Launches Contract Research Services Business for Biomolecular Interaction Studies

January 16, 2013

Plexera®, LLC, a worldwide provider of label-free surface plasmon resonance imaging (SPRi) technology solutions for functional proteomics, announced today the official launch of its contract research effort based in offices of Plexera LLC located at the Institute for Systems Biology (ISB). Plexera will perform advanced kinetic interaction analysis on either customer provided samples or Plexera provided targets and libraries.

Seattle Washington (PRWEB) January 16, 2013

Plexera®, LLC, a worldwide provider of label-free surface plasmon resonance imaging (SPRi) technology solutions for functional proteomics, announced today the official launch of its contract research effort based in offices of Plexera LLC located at the Institute for Systems Biology (ISB). Plexera will perform advanced kinetic interaction analysis on either customer provided samples or Plexera provided targets and libraries.

“Through the use of array-formatted label-free, real-time detection and a diverse choice of surface chemistries, customers can avoid the changes to molecular interactions introduced by chemical and biological labeling techniques” says Dr. Zhang, director of Applications at Plexera.

Applications include high-throughput screening, affinity analysis, and specificity determination. Complete service provides custom NanoCapture® chip chemistry selection and preparation, ligand generation and characterization, multiple array production, full kinetic data and analysis, and a full service report. Plexera will take advantage of extensive laboratory facilities at ISB to offer customers a fully integrated service including immunoassay and MS analysis in addition to SPRi studies. The company has completed several studies to date including , small molecule screening, glycoprotein profiling , antibody epitope mapping, and pair antibody screening, and is also aggressively forming collaborative partnerships with leading academic institutions in the US and Asia. Most recently the company shipped and installed a system at RIKIN in Japan to study small molecule/protein binding interactions. The company also announced it has manufactured and shipped its 18th PlexArray® HT system since launched in 2011 and has been awarded its 11th patent surrounding the SPRi technology.

“We are very pleased with the depth of our patent portfolio and the ever increasing inventory of application developments we have made over the last year.” Says Dr. Jinsong Zhu, CEO, Plexera LLC. “As indicated by customer interest the HT application for interaction studies is certainly an emerging commercial technology today.”

ABOUT PLEXERA, LLC.

Plexera LLC (http://www.plexera.com) is a Washington state company providing advanced SPRi-based solutions for functional proteomics. The company has development and manufacturing facilities at its headquarters in Woodinville, WA and has application laboratories in Seattle at the Institute for Systems Biology. The company is exclusively represented for development and marketing in Guangzhou, China by Guangzhou Gaotong Biotechnology Co., Ltd. and PuRui TongLiang Beijing Biotechnology company Ltd. in Beijing. In Japan, the company is exclusively represented by Cell Produce Co., Ltd.

The PlexArray® HT System is a high-throughput, label-free, SPR-based biomolecular interaction detection system for producing high quality information on kinetics, affinities, and specificities among proteins, peptides, small molecules, and genetic materials. The PlexArray HT serves a wide range of industries including pharmaceutical, biomarker R&D, and assay development. A variety of samples can be measured in 15 minutes and thousands of molecule interactions in only 30 minutes. NanoCapture® Biosensor Chips feature high array density (>1,000 spots interrogated simultaneously), variable array spot size (100 μm), and multiple surface chemistries for protein, nucleic acid, small molecule, or live cell immobilization.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/1/prweb10320468.htm


Source: prweb



comments powered by Disqus